INFECTION PREVENTION


“impregnate the entire indwelling surface length of the catheter,” according to the company’s description.


Arrowg+ard Blue Plus Protection, the


line of CVC products offered by Teleex, includes citations and summaries for research that has found the technology to be effective. Those include studies pub- lished in Association for Vascular Access (AVA), Intensive Care Medicine, and the American Journal of Infection Control. Scott Schneider, Vice President of


Sales for Teleex, “are making the big- gest impact on patient care and hospital performance. The real benefits, he said, “are that they protect the patient while providing procedural efficiency for our clinicians.” ecton, Dickinson and Company (D) announced early last year (2021) results of a clinical trial, now published in The Lancet Infectious Diseases, which found that the risk of peripheral IV catheter (PIVC) failure can be reduced by 27% — resulting in longer catheter dwell times without complications — with four BD products, used in tandem.


“The problem with PIVC lines is that they often fail prematurely,” said Dr.


BD integrated solution: • Establish patient IV line using BD Nexiva catheter


• Attach BD MaxZero needle-free connector • Flush IV line


Klaus Hoerauf, Vice President of Global Medical Affairs at BD. PIVC re-insertions can be painful, and may raise the probability that additional complications will develop. CDC guidelines recommend that PIVCs


be replaced no more frequently than every 72 to 96 hours.2 The CLEAN33


study, funded by BD but


designed and conducted independently, included about 1,000 participants in a French university hospital. Both compara- tive dwell times and antiseptic solution effectiveness were examined. Use of the BD “integrated solution” resulted in fewer peripheral intravenous catheter (PIVC) failures compared with the standard group (34.8% vs. 47.5%. respectively) and extended median times between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively), according to the study’s findings. “The whole goal of the study was to


compare two peripheral vascular care approaches — an integrated product solution versus the hospital’s standard approach — in preventing complica- tions that lead to peripheral IV catheter failure,” Hoerauf said.


• Inject patient medication • Flush line again • Place disinfecting cap onto needle-free connector


CLEAN3 included the use of some of BD’s own products as part of that control group. They were used independent of a prescribed product combination. The trial found the use of 2% chlorhex- idine-gluconate (CHG) 70 % isopropyl alcohol (IPA) single use, sterile applicator skin, antiseptic reduced the risk of infec- tious complications by 92% compared with 5% povidone iodine (PVI) 69% ethanol.


The four-product regimen tested as


part of the CLEAN3 trial includes PIVC (BD Nexiva), needle-free connector (BD MaxZero), disinfecting cap (BD PureHub) and a sterile prefilled ush syringe (D Posiush).


According to the trial summary, use of the integrated solution — or care bundle — is the best practice standard when peripheral IV catheter dwell time is expected to last more than 24 hours. More than a billion PIVCs are inserted each year in hospitalized patients world- wide, according to the Journal of Hospital Medicine.3


Leadership is key Not long after the TGH team was honored by APIC, Galvan was named as the orga- nization’s inaugural “Emerging Leader in Infection Prevention.” According to the commendation, Galvan, “managed performance improve- ment proects that have reduced the risk of patient harm and resulted in impres- sive outcomes such as a significant reduc- tion in catheter-associated urinary tract infections, a reinvigorated hand hygiene compliance program, and a culture shift toward shared accountability with hospi- tal cleanliness.”


Galvan shrugs off the accolade. After all, pathogen patrol is never done. He’s sanguine about the future. People after all, may be wiser from having endured nearly two years of pandemic crises.


“Everyone is more savvy now in their understanding about healthcare,” he said. HPN


Reference:


1. https://www.cdc.gov/hai/data/portal/progress-report. html


2. CDC Guidelines for the Prevention of Intravascular Catheter- Related Infections, 2011https://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5110a3.htm


3. https://www.journalofhospitalmedicine.com/jhospmed/ article/127821/prevalence-use-pivcs


hpnonline.com • HEALTHCARE PURCHASING NEWS • January 2022 23


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52